Dear Rudy:
I do hope AMLN's European trial for type I will be better, too. In fact it is not just hope, it got the following three reasons.
1. It is for patients with HbA1c of 8% or higher only, so the .4% should be the bottomline here, no more .3%.
2. Attempt to control insulin for stable dosage. It can not be controlled totally, let's face it. But, any control that will help the drug group and control group to use closer amounts of insulin will help the outcome. Better control, better outcome. Great control, great outcome. They may not get great control, but I think improvement for sure.
3. According to an old H&Q report, the dosage of pramlintide is spread out this time, in one group, the dose is as high as more than twice of the first trial dose. As we saw some dosage correlation in type II in the first trial (from 30 gram group up), the higher dose may work much better.
Of course these are just possibilities. But they are based on last trial result. As I said before, I feel much better with the last trial result than without it. At least we are not totally in the dark.
Good night
D.Right |
